Private: Atopic Dermatitis (Eli Lilly and Company Study)
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
Trial available at the following locations:
Phoenix 7th,
Learn More
Phoenix 7th,